Axsome Therapeutics Inc (AXSM)
77.24
-1.26
(-1.61%)
USD |
NASDAQ |
Jun 26, 10:33
Axsome Therapeutics SG&A Expense (Annual): 323.12M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 323.12M |
| December 31, 2022 | 159.25M |
| December 31, 2021 | 66.65M |
| December 31, 2020 | 28.90M |
| December 31, 2019 | 13.60M |
| December 31, 2018 | 9.352M |
| Date | Value |
|---|---|
| December 31, 2017 | 7.207M |
| December 31, 2016 | 6.344M |
| December 31, 2015 | 2.419M |
| December 31, 2014 | 1.393M |
| December 31, 2013 | 0.3042M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
13.60M
Minimum
2019
323.12M
Maximum
2023
118.30M
Average
66.65M
Median
2021
SG&A Expense (Annual) Benchmarks
| Krystal Biotech Inc | 98.40M |
| AbbVie Inc | 12.87B |
| Viking Therapeutics Inc | 37.02M |
| Alnylam Pharmaceuticals Inc | 795.65M |
| Catalyst Pharmaceuticals Inc | 133.71M |